- Home
- SWVL vs HIND Comparison
SWVL vs HIND Comparison
Compare SWVL & HIND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SWVL | HIND |
|---|---|---|
| Founded | 2017 | 2017 |
| Country | United Arab Emirates | United States |
| Employees | 284 | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6M | 12.9M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | SWVL | HIND |
|---|---|---|
| Price | $1.80 | $2.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | ★ 21.4K | 15.2K |
| Earning Date | 04-20-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.31 | $1.75 |
| 52 Week High | $4.99 | $12.87 |
Technical Indicators
Market Signals| Indicator | SWVL | HIND |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 45.61 |
| Support Level | $1.33 | $2.02 |
| Resistance Level | $3.83 | $2.43 |
| Average True Range (ATR) | 0.14 | 0.17 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 72.82 | 48.78 |
Price Performance
Historical ComparisonAbout SWVL Swvl Holdings Corp
Swvl Holdings Corp is a technology-driven mobility company that aims to provide reliable, safe, cost-effective and environmentally responsible mass transit solutions. It provides mobility solutions for enterprises and government and individual commuters across-multiple markets with clients such as Amazon, Bosch, E&, P&G and Siemens. The Company operates in Egypt, Saudi Arabia and the UAE.
About HIND Vyome Holdings Inc.
Vyome Holdings Inc is a reseach and development company. The Company operates in two segments, biotechnology and pharmaceutical products. The biotechnology segment comprises of operations around VT-1953, VT-1908, and VB-1953 programs that are in development, and the pharmaceutical segment comprises of antifungal products manufacturing and distribution.